IP Library Granted Patent US 9,011,361
Granted Patent B2
US 9,011,361 · App. 12/231,987 · Granted Apr 21, 2015

Lacrimal implant detection

Inventors: Eugene de Juan, Jr. (San Francisco, CA); Stephen Boyd (Murrieta, CA); Cary J. Reich (Los Gatos, CA); Christopher V. Cardenas (Redwood City, CA); Tommy Jewell (Albuquerque, NM); Lorrie Ma (San Jose, CA); Ngoc-Tuan Nguyen (San Jose, CA)
Assignee: Mati Therapeutics Inc.
A61F9/00772A61B5/0031A61B5/06A61B5/411A61B8/0833A61B2562/08A61F9/0017G01R33/0213G01R33/072
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,011,361
App. No.
12/231,987
Granted
Apr 21, 2015
Kind
B2
Abstract

This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.

Claims (43)

1. A lacrimal implant comprising:

a punctal plug insertable at least partially into a lacrimal punctum, the punctal plug comprising:

an implant core comprising a matrix;

a sheath body partially surrounding the implant core;

a plug body, wherein the plug body includes a cavity sized and shaped to receive the implant core,

the implant core disposed within the cavity, and

a contrast agent configured to allow detection of the punctal plug with a separate detector device, wherein the contrast agent is present in at least one of the implant core and the plug body and configured to optically distinguish the lacrimal implant from a region of an eye.

2. The lacrimal implant of claim 1 , wherein the contrast agent includes a material visible when illuminated with a 600-1300 nanometer light source.

3. The lacrimal implant of claim 1 , wherein the implant core further comprises a sustained release ocular agent.

4. The lacrimal implant of claim 1 , wherein the contrast agent is disposed within the sheath.

5. The lacrimal implant of claim 1 , wherein the contrast agent comprises a color material, a pigment or a dye.

6. The lacrimal implant of claim 3 , wherein the sustained release ocular agent comprises travoprost, NSAIDs, anti-glaucoma drugs, prostaglandin analogues, cycloplegic drugs, or mydriatic drugs.

7. A lacrimal implant comprising:

a green punctal plug insertable at least partially into a lacrimal punctum, comprising:

an implant core comprising a silicone matrix and latanoprost;

a sheath body partially surrounding the implant core;

a plug body of biocompatible material, wherein the plug body includes a cavity sized and shaped to receive the implant core;

the implant core disposed within the cavity, wherein the green punctal plug is distinguished from a region of an eye.

8. A lacrimal implant comprising:

a punctal plug insertable at least partially into a lacrimal punctum, the punctal plug comprising:

an implant core comprising a matrix and a therapeutic agent;

a sheath body partially surrounding the implant core;

a plug body, wherein the plug body comprises a cavity configured to receive the implant core; and

the implant core disposed with the cavity,

wherein at least one of the implant core or the plug body comprises a contrast agent, which is configured to optically distinguish the punctal plug from a region of an eye.

9. The lacrimal implant of claim 8 , wherein the sheath body is substantially impermeable to the therapeutic agent.

10. The lacrimal implant of claim 8 , wherein the lacrimal implant is a green punctual plug.

11. The lacrimal implant of claim 8 , wherein the matrix comprises silicone.

12. The lacrimal implant of claim 8 , wherein the therapeutic agent comprises NSAIDs, anti-glaucoma drugs, prostaglandin analogues, cycloplegic drugs, or mydriatic drugs.

13. The lacrimal implant of claim 8 , wherein the therapeutic agent is latanoprost or travoprost.

14. The lacrimal implant of claim 8 , wherein the contrast agent comprises a color material, a pigment, or a dye.

15. The lacrimal implant of claim 14 , wherein the contrast agent is disposed on a surface of the implant core.

16. The lacrimal implant of claim 14 , wherein the contrast agent is disposed on a sheath body of the implant core.

17. The lacrimal implant of claim 14 , wherein the contrast agent is disposed in the matrix of the implant core.

18. The lacrimal implant of claim 14 , wherein the contrast agent is disposed in the plug body.

19. The lacrimal implant of claim 14 , wherein the contrast agent comprises a material visible when illuminated with a visible light source.

20. The lacrimal implant of claim 19 , wherein the visible light source is an LED.

21. The lacrimal implant of claim 14 , wherein the, contrast agent comprises a material visible when illuminated with a 600 to 1300 nanometer light source.

22. The lacrimal implant of claim 3 , wherein the sustained release ocular agent is latanoprost.

23. The lacrimal implant of claim 22 , wherein the latanoprost is liquid latanoprost droplets dispersed in a non-biodegradable silicone matrix.

24. The lacrimal implant of claim 23 , wherein the latanoprost is released at therapeutic levels to the eye when the punctal plug is implanted into a lacrimal punctum.

25. The lacrimal implant of claim 13 , wherein the therapeutic agent is liquid latanoprost droplets dispersed in a non-biodegradable silicone matrix.

26. The lacrimal implant of claim 25 , wherein the latanoprost is released at therapeutic levels to the eye when the punctal plug is implanted into a lacrimal punctum.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2013
From: QLT INC.
To: MATI THERAPEUTICS INC.
Reel/Frame 030266/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: 3088922, INC.
To: QLT INC.
Reel/Frame 026182/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: QLT PLUG DELIVERY, INC.
To: 3088922, INC.
Reel/Frame 026182/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2008
From: DE JUAN, EUGENE; BOYD, STEPHEN; REICH, CARY J.; CARDENAS, CHRISTOPHER V.; JEWELL, TOMMY; MA, LORRIE; NGUYEN, NGOC-TUAN
To: QLT PLUG DELIVERY, INC.
Reel/Frame 022014/0641 →
Continuity (3)
Provisional Application 60970807 · Sep 7, 2007
Provisional Application 61050901 · May 6, 2008
Related Publication 20090099626A1 · Apr 16, 2009